Abcam, ab263236, Human ITFG1 (CDA08) knockout HeLa cell lysate

Size: 1Kit
ITFG1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Insertion of the selection cassette in exon1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Insertion of the selection cassette in exon1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ITFG1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CDA08 also known as cytidine deaminase weighs approximately 16 kDa and is expressed mainly in the spleen liver and bone marrow. This enzyme catalyzes the deamination of cytidine transforming cytidine into uridine and plays a role in nucleotide metabolism. By conducting this reaction CDA08 regulates cytidine and deoxycytidine levels impacting DNA and RNA synthesis.
Biological function summary
The enzyme CDA08 modulates cell proliferation and apoptosis through its regulation of nucleotide pools. It is not part of any known larger protein complex standing as a singular enzyme in its function. CDA08 activity influences the balance between pyrimidine metabolites impacting cellular functions such as DNA repair and replication.
Pathways
Scientists have linked CDA08 to the pyrimidine metabolism and nucleic acid synthesis pathways. Its activity integrates with key enzymes in these processes maintaining cellular nucleotide homeostasis. Additionally proteins like ribonucleotide reductase interact functionally with CDA08 showing a coordinated regulation of deoxycytidine triphosphate levels essential for DNA synthesis.
Researchers have connected CDA08 with acute myeloid leukemia and certain lymphomas. Alterations in CDA08 expression or activity can affect chemotherapeutic drug metabolism influencing treatment outcomes. Furthermore proteins such as deoxycytidine kinase are related to CDA08 through their roles in these disorders linking drug resistance mechanisms with nucleotide metabolism.